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Cerebrovascular inﬂammationAccumulation of amyloidogenic Ab peptides in the brain contributes to the onset of Alzheimer dis-
ease. Ab peptide deposits are also present in blood vessel walls, mainly deriving from circulating
platelets. However, their effect on platelet function is unclear. We demonstrate that immobilized
Ab peptides induce platelet adhesion and spreading through metalloproteinase-sensitive surface
receptors. Ab peptides also fasten platelet spreading on collagen, and support the time- and ADP-
dependent activation of adherent platelets, leading to stimulation of several signalling proteins.
Our results indicate a potential role for peripheral Ab peptides in promoting platelet adhesion
and activation in the initiation of thrombus formation.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction previous study has demonstrated that aggregated Ab peptides, asAmyloidogenic Ab are heterogeneous peptides deriving from
the amyloidogenic proteolysis of the amyloid precursor protein
APP, and accumulate in the senile plaques in the brain during the
onset of Alzheimer disease (AD) [1]. Ab peptides are also present
in small arteries and capillaries of leptomeninges and cerebral cor-
tex, causing cerebral amyloid angiopathy [2], and are involved in
the inﬂammatory pathology of atherosclerotic vascular disease
[3]. Amyloid Ab peptides present in the bloodstream mainly derive
from circulating platelets. Platelets express amyloid precursor pro-
tein APP751 and APP770, as well as all the enzymes for APP proteol-
ysis through amyloidogenic and non-amyloidogenic pathways [4].
In addition, a considerable amount of amyloidogenic Ab1–40 and
Ab1–42 peptides is stored in platelet a-granules and is secreted
upon platelet stimulation [3,5,6]. Once released in the plasma, Ab
peptides are able to induce platelet activation, establishing a posi-
tive feedback to potentiate cell activation. The mechanism by
which Ab peptides trigger platelet activation is unknown. Aother misfolded proteins, induce platelet activation through two
different pathways initiated by CD36 or GPIb, respectively [7].
Shen and collaborators have demonstrated that the ability of
Ab1–40 to promote platelet activation and to potentiate the effect
of weak agonists is completely conserved by the smaller Ab25–35
peptide, a fragment of 11 amino acids corresponding to the inter-
membrane segment of the entire peptide [8]. It is now clear that
Ab25–35 reproduces all the biological functions of Ab peptides, as
it also retains the toxicity of the entire peptides and is able to
aggregate innately in ﬁbrils with b-structure [9]. Ab25–35 is also
physiologically present in elderly people, suggesting its impor-
tance in the pathogenesis of AD [10,11].
In the present study we have investigated the ability of different
heterogeneous amyloidogenic peptides, Ab1–40, Ab1–42 and the
short Ab25–35 immobilized on coated dishes to promote speciﬁc
platelet adhesion, spreading and activation, in order to clarify their
potential role in the early phases of thrombus formation.2. Materials and methods
2.1. Materials
Ab1–40, Ab1–42 and Ab25–35, bovine serum albumin (BSA),
dimethylsulfoxide (DMSO), prostaglandin E1, apyrase, indometacin,
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purchased from Sigma–Aldrich. W7 was from Alexis. Monomeric
type I collagen was provided by Prof. M.E. Tira (University of Pavia,
Pavia, Italy). The rabbit polyclonal Abs against Rap1(121), as well as
the mAb anti-tubulin (DM1A) were from Santa Cruz Biotechnology.
Anti phospho-Akt(S473), anti phospho-p38MAPK(T180/Y182), anti
phospho-ERK1/2(T202/Y204), anti phospho-MLC(S19) and anti PKC
phospho-substrates were from Cell Signaling Technology. Appro-
priate peroxidase-conjugated anti-IgG Abs were from Bio-Rad.
The bicinchoninic acid assay was from Pierce and the enhanced
chemiluminescence substrate was from Millipore.
2.2. Preparation of washed human platelets
Human platelets were obtained from healthy volunteers
(<60 years) enrolled by the local hospital. Whole blood in citric
acid/citrate/dextrose (152 mM sodium citrate, 130 mM citric acid,
112 mM glucose) was centrifuged at 120g for 10 min at room
temperature. Apyrase (0.2 units/ml), prostaglandin E1 (1 lM), and
indometacin (10 lM) were then added to the platelet-rich plasma.
Platelets were recovered by centrifugation at 720g for 15 min,
washed with 10 ml of PIPES buffer (20 mM PIPES, 136 mM NaCl,
pH 6.5), and ﬁnally gently resuspended in HEPES buffer (10 mM
HEPES, 137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, pH 7.4)Fig. 1. Immobilized amyloid peptides Ab25–35, Ab1–40 and Ab1–42 support platelet adhesi
Ab25–35, Ab1–40, Ab1–42 or 0.5% BSA, as indicated, for different time. Adherent platelets wer
images at 1000 magniﬁcation of adherent platelets to the indicated substrates after 60
double white arrows, respectively. (B) Quantiﬁcation of platelets adhesion, evaluated as
area is reported in panels (i) and (ii), respectively.containing 1 mM CaCl2. The cell count was typically adjusted to
3  108 platelets/ml unless otherwise stated.
2.3. Adhesion assay
Polystyrene dishes (60 mm) were coated overnight at room
temperature with 25–50 lg/ml of collagen type I, or 5–10 lM
Ab1–40, Ab1–42 and Ab25–35, (as indicated) diluted in PBS, and then
blocked with 1% BSA for 2 h at room temperature. Washed human
platelets (0.5 ml) were added to Ab- or collagen-coated dishes in
the presence of 1 mM CaCl2 or of 1 mM MgCl2 and 1 mg/ml of
BSA, respectively. After incubation at room temperature for 10–
60 min, non-adherent cells were discharged, and adherent cells
were directly solubilized with 0.3 ml of 2% SDS, for whole cell ly-
sates preparation. For analysis of Rap1 activation, adherent plate-
lets were lysed with 0.3 ml of ice-cold RIPA buffer (50 mM Tris/
HCl, pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 1% Nonidet P-40, 10%
glycerol, 1 mM PMSF, 5 lg/ml leupeptin, 5 lg/ml aprotinin, and
2 mM Na3VO4) and lysates were centrifuged at 18000g for
10 min. Aliquots of each sample containing the same amount of
proteins were used for immunoblotting analysis or for Rap1b acti-
vation assay, as previously described [12].
Evaluation of platelet adhesion and spreading was performed
using a ﬂuorescence microscopy-based method after incubationon. (A) Washed human platelets were plated on glass coverlips coated with 10 lM
e ﬁxed, permeabilized and stained with TRITC conjugated phalloidin. Representative
min are reported. Filopodia and lamellipodia formation are indicated by single and
number of adherent platelets, and platelets spreading, evaluated as mean platelet
Fig. 2. Effect of calmodulin antagonist W7 on platelet adhesion to amyloid peptide Ab25–35. Platelets were preincubated with vehicle (DMSO) or with 100 lM calmodulin
antagonist W7 for 30 min and let to adhere to immobilized Ab25–35. Adherent platelets were ﬁxed, permeabilized and stained with TRITC conjugated phalloidin and adhesion
and spreading were evaluated in ﬂuorescence microscopy. Representative images (400) are reported in A, and quantiﬁcation of adhesion and spreading, as means ± S.D. of
three different experiments, is reported in B (i) and (ii), respectively. ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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peptides. Adherent platelets were ﬁxed, permeabilized with Triton
X-100, and stained by TRITC-conjugated phalloidin, as previously
described [13]. Platelets were viewed on a ﬂuorescence microscope
(Olympus BX51), and digital images (400, 1000) were acquired.
The number of adherent cells, as well as the average cell area (as an
index of platelet spreading), was determined using the ImageJ Ver-
sion 1.42 software. For each specimen, ﬁve different ﬁelds were
analyzed by two independent observers. Statistical analysis was
performed using Prism Version 4 software (GraphPad) and the data
were compared by unpaired t test.
2.4. Electrophoresis and immunoblotting
Aliquots of platelet lysates containing the same amount of
proteins were separated by SDS–PAGE on 5–15% acrylamide gels,
and transferred to PVDF membrane. Immunoblotting analysis
was performed as previously described [12], using the following
antibodies and dilutions: anti-phospho-Akt(S473), anti-phospho-
p38MAPK(T180/Y182), anti-phospho-ERK1/2(T202/Y204), and
anti-phospho-MLC(S19): 1:500; anti PKC phospho-substrates, anti
tubulin (DM1A), and anti Rap1(121): 1:1000. Reactive proteins
were visualized with a chemiluminescence reaction. All of the
immunoblots are representative of at least three different experi-
ments giving similar results.
3. Results
3.1. Platelets adhere to immobilized Ab peptides
Human washed platelets were let to adhere to dishes coated
with the amyloidogenic peptides Ab1–40, Ab1–42, and Ab25–35.
Fig. 1A shows representative images of adherent platelets on the
three different Ab peptides, upon staining with TRITC-conjugated
phalloidin. A comparable number of adherent platelets can be ob-
served on the three substrates, which was clearly higher than thatseen on control BSA. Many of these cells are characterized by the
extrusion of ﬁlopodia (single arrows), and by the formation of
lamellipodia (double arrows) indicating that adhesion on Ab pep-
tides induced the typical changes in the platelet shape characteris-
tic of the cell spreading [14]. The number of adherent platelets
which is directly related to the percentage of adherent platelets,
have been quantiﬁed and results are reported in panel (i) of
Fig. 1B. In time course experiments, the number of platelets adher-
ent to Ab25–35 and Ab1–40 increased progressively from 10 to
60 min. This ﬁnding was conﬁrmed by calculation of the percent-
age values of adherent platelets which increase progressively with
time with no signiﬁcant differences among different peptides
(Ab25–35: 10 min, 7.7% ± 1.8; 30 min, 15.51% ± 3.2; 60 min,
24.9% ± 1.79; Ab1–40: 10 min, 7.63% ± 2.1; 30 min, 12.71% ± 4.1;
60 min, 26.73% ± 3.8; Ab1–42: 60 min, 26.4% ± 1.6).
The mean platelet area, which is indicative of platelet spread-
ing, was also measured. Platelet spreading occurred rapidly and
was comparable at all the time point analyzed, indicating that
adherent platelets rapidly undergo activation. Quantitative analy-
sis performed after 60 min of incubation revealed that the number
of platelets adherent to Ab25–35, Ab1–40, and Ab1–42 was signiﬁ-
cantly higher than the non-speciﬁc interacting with immobilized
BSA.
Since these results revealed that the different Ab peptides
tested were similarly efﬁcient in promoting platelet adhesion and
spreading, subsequent experiments were performed using immo-
bilized Ab25–35.
To verify whether the adhesion and activation of platelets on
Ab25–35 peptide was initiated by the engagement of a membrane
receptor or was consequent of a nonspeciﬁc absorption or pertur-
bation of the cell membrane, we treated platelets with the calmod-
ulin inhibitor W7 able to induce metalloproteinase-mediated
shedding of several membrane glycoproteins, including GPIb, GPVI
and APP itself [15,16]. Fig. 2 shows that 100 lMW7 almost com-
pletely abolished platelet adhesion to immobilized Ab25–35 and sig-
niﬁcantly impaired spreading.
Fig. 3. Amyloid peptide Ab25–35 accelerates platelets spreading on collagen type I. (A) Platelets were let to adhere to glass coverlips coated with 25 lg/ml collagen (black
bars), 5 lMAb25–35 (gray bars) or a combination of both (white bars), and platelet adhesion (i) and spreading (ii) were analyzed. (B) Washed platelets untreated (black bars) or
stimulated with 10 lM Ab25–35 (white bars) were let to adhere to 50 lg/ml collagen type I coated glass coverlips and adhesion (i) and spreading (ii) were analyzed. In all the
histograms, data are reported as mean ± S.D. of three different experiments. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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Amyloid peptides accumulate in vascular deposits and in aortic
atherosclerotic lesions, in association with other subendothelial
components. We therefore analyzed whether the presence of
Ab25–35 was able to increase the thrombogenic potential of extra-
cellular matrices. Dishes were coated with ﬁbrillar type I collagen,
with Ab25–35, or with both substrates, and platelets were let to ad-
here for increasing times. Fig. 3A show that at all the time point
analyzed, the ability of Ab25–35 to support platelet adhesion was
comparable to that of type I collagen, a potent thrombogenic pro-
tein. However, the concomitant presence of collagen type I and
Ab25–35 on the same dishes did not cause any increase of the num-
ber of adherent platelets (percentage of adhesion at 30 min: colla-
gen, 15.09% ± 0.64; Ab25–35, 12.58% ± 1.41; collagen + Ab25–35,
13.22% ± 0.52). Nevertheless, the presence of immobilized Ab25–35
clearly potentiated the collagen-induced spreading of adherent
cells (Fig. 3Aii). This potentiating effect was more pronounced at
early time points, indicating that the concomitant presence of
the two substrates accelerated the activation of adherent platelets.
The interplay between Ab25–35 and collagen in the regulation of
platelet spreading was also conﬁrmed through the analysis of the
effect of platelet treatment with soluble amyloidogenic Ab peptide
on the interaction with immobilized type I collagen. Fig. 3B shows
that prestimulation of platelets with Ab25–35 did not modify
platelet adhesion on collagen (percentage of adhesion at 30 min:collagen, 13.61% ± 1.24; collagen + Ab25–35, 13.59% ± 0.95) but re-
sulted in acceleration of platelet spreading (Fig. 3Bii).
3.3. Adhesion to Ab25–35 stimulates platelet activation
We next investigated the ability of Ab peptides to activate sig-
nalling pathways in the adherent platelets. Platelets were let to ad-
here to Ab25–35, and the phosphorylation of selected signalling
protein was analyzed by immunoblotting. We found that Ab25–35
stimulated both PI3K and MAPkinase pathways in adherent plate-
lets, because a time-dependent phosphorylation of Akt, p38MAP-
kinase, and ERK1/2 was observed (Fig. 4A). Interestingly, Ab25–35-
induced phosphorylation of these substrates was strongly reduced
in the presence of the ADP scavenger apyrase, indicating that, as for
many other soluble agonists, the positive feedback initiated by se-
creted ADP plays a critical role (Fig. 4A). The effect of secreted ADP,
however, was not consequence of a reduced platelet adhesion, as
we found that the ability of platelets to adhere to immobilized
Ab25–35 was not altered in the presence of apyrase (Fig. 4B). Adhe-
sion to Ab25–35 also caused the time-dependent phosphorylation of
the cytoskeletal protein myosin light chain, which was only par-
tially regulated by secreted ADP. This observation is in line with
the ability of Ab25–35 to promote the reorganization of the platelet
morphology supporting cell spreading. Phosphorylation of myosin
light chain is typically triggered by intracellular Ca2+ elevation
through stimulation of PLC. In order to verify whether Ab25–35
Fig. 4. Adhesion to amyloid peptide Ab25–35 stimulates platelet activation. (A and C) Aliquots of whole lysate from adherent platelets to Ab25–35 (adherent platelets) were
analyzed by immunoblotting with the antibodies indicated in the right. Non-adherent platelets (NA) were loaded as negative control. (B) Analysis of platelet adhesion to
immobilized Ab25–35 in the presence (white bars) or absence (black bars) of 2 U/ml apyrase. D) Rap1b activation (GTP-Rap1b) was evaluated by pull down assay on adherent
cells followed by immunoblotting with anti-Rap1b antibody. The lower panel (Rap1b) shows the amount of the total protein in the cell lysates.
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uated the activity of PKC, a target for PLC-generated diacylglycerol.
Fig. 4C shows that platelet adhesion to Ab25–35 induced a time-
dependent phosphorylation of several PKC substrates, including
the 47 kDa protein pleckstrin. This effect was only partially re-
duced in the presence of apyrase. Finally, we found that Ab25–35
promoted also the activation of the small GTPase Rap1b, a key reg-
ulator of several platelet function, including secretion and integrin
aIIbb3 activation [17]. Also in this case, accumulation of active
GTP-bound Rap1b was largely dependent on secreted ADP
(Fig. 4D).
4. Discussion
In this study we have investigated the potential role of amylod-
ogenic peptides in the initial phase of thrombus formation, and we
have demonstrated that human platelets are actually able to ad-
here and spread over immobilized Ab peptides. We have adopted
an experimental model, consisting in platelet adhesion assays to
Ab-coated dishes, that has never been explored so far, and reliably
simulates the deposition of insoluble Ab peptides in the blood ves-
sel or in atherosclerotic plaques. We have demonstrated that plate-
lets adhere to immobilized neurotoxic Ab1–40, to the more
ﬁbrillogenic Ab1–42, as well as to the shorter fragment Ab25–35, with
a comparable efﬁciency. Upon adhesion to all these Ab peptides,
platelets similarly undergo spreading through the elongation of ﬁl-
opodia and lamellipodia, an event triggered by adhesion-depen-
dent cell activation. Importantly, all these peptides revealed to be
as potent inductors of platelet adhesion and spreading as type I
collagen, the most common component of the extracellular matrix.
This observation indicates that the ability of Ab peptides trapped
into insoluble matrices to initiate platelet recruitment may bephysiologically relevant, as it is comparable to that of a well-de-
ﬁned thrombogenic protein. Moreover, the presence of immobi-
lized Ab can potentiate the spreading of platelets on type I
collagen, and a similar effect is also promoted by preincubation
of platelets with soluble Ab. Therefore, it is clear that in the pres-
ence of a collagen-based matrix both immobilized Ab or soluble
Ab can fasten and potentiate activation of adherent platelets and
thus accelerate thrombus formation.
Previous reports have suggested that Ab25–35 promotes aggrega-
tion of a suspension of washed platelets through thrombin recep-
tor PAR1 [8], whereas others have demonstrated the involvement
of glycoprotein Iba(GPIba) and the scavenger receptor CD36 [7].
Evidence indicate that ﬁbrillar amyloid b protein is also able to
bind the extracellular domain of its precursor, APP [17,18]. We
have demonstrated herein that platelet adhesion and spreading
over Ab covered surfaces is strongly reduced by the calmodulin
antagonist W7, a drug that promotes shedding of several glycopro-
teins, including GPIba and the amyloid precursor protein APP
[15,16]. Our results thus allow to narrow the list of potential recep-
tors for Ab, and are consistent with the possibility that Ab actually
binds its precursor APP, as previously suggested [19]. However, in
preliminary experiments, incubation of platelets with the anti-APP
monoclonal antibody 22C11 did not alter platelet adhesion to
Ab25–35 (data not shown). Therefore, the precise identiﬁcation of
the speciﬁc receptor responsible for adhesion of platelets to Ab
peptides requires further investigation.
An additional important ﬁnding of our study is that platelet
adhesion to immobilized Ab activates intracellular signalling path-
ways associated with platelet stimulation. We documented that, as
many potent platelet agonists, immobilized Ab can trigger the acti-
vation of the lipid metabolizing enzymes PLC and PI3K as well as
the stimulation of MAP kinases and Rap1b GTPase. Therefore,
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factor for platelet activation in the initiation of thrombus forma-
tion. Importantly, many of these stimulatory events elicited by
platelet adhesion to Ab are signiﬁcantly potentiated by secreted
ADP. This opens the possibility to counteract the pro-thrombotic
effects of immobilized Ab peptides by classical ADP receptor antag-
onists, which represent well characterized anti-platelet agents.
In conclusion, our results demonstrated for the ﬁrst time that
deposits of Ab peptides, as may occur in blood vessels wall of AD
patients and in atherosclerotic lesions, can actively reinforce plate-
let adhesion and activation at the site of vascular injury, and there-
fore contribute to a vicious cycle to chronic inﬂammation and
degeneration.
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